Sinovac Biotech (Sinovac Biotech) EBIT per Share : $-8.44 (TTM As of Jun. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Sinovac Biotech EBIT per Share?

Sinovac Biotech's EBIT per Share for the six months ended in Jun. 2023 was $-0.56. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $-8.44.

During the past 12 months, the average EBIT per Share Growth Rate of Sinovac Biotech was -118.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Sinovac Biotech's EBIT per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Sinovac Biotech was 503.90% per year. The lowest was -128.90% per year. And the median was 29.10% per year.

SVA's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.4
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Sinovac Biotech's EBIT for the six months ended in Jun. 2023 was $-63.3 Mil.

Sinovac Biotech EBIT per Share Historical Data

The historical data trend for Sinovac Biotech's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinovac Biotech EBIT per Share Chart

Sinovac Biotech Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT per Share

Get a 7-Day Free Trial

0.73

0.65

1.92

154.08

0.23

Sinovac Biotech Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EBIT per Share	Get a 7-Day Free Trial															89.14	64.93	8.12	-7.89	-0.56

Sinovac Biotech EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Sinovac Biotech's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

	EBIT per Share		(A: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	26.502	/	114.173
=	0.23

Sinovac Biotech's EBIT per Share for the quarter that ended in Jun. 2023 is calculated as

	EBIT per Share		(Q: Jun. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-63.346	/	114.227
=	-0.55

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-8.44

Sinovac Biotech (NAS:SVA) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Sinovac Biotech EBIT per Share Related Terms

Thank you for viewing the detailed overview of Sinovac Biotech's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinovac Biotech (Sinovac Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinovac Biotech Ltd (NAS:SVA) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085

Website

http://www.sinovac.com

Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.

Executives

Lily Wang	director, 10 percent owner, officer: Chief Financial Officer	300 MURCHISON DR., MILLBRAE CA 94030
Ifg Investments Services Inc	10 percent owner	PO BOX 822, CHARLESTOWN FEDERATION OF ST KITTS & NEVIS WEST INDIES P8 00000
Yin Weidong	director, 10 percent owner, officer: President and CEO
Terry G Bowering	director, 10 percent owner, officer: President, CEO	10 CEDAR MEADOW DRIVE REGINA A9 S4X 3J6